 | • レポートコード：GIR201102393 • 出版社/出版日：GlobalInfoResearch / 2020年10月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、136ページ • 納品方法：Eメール • 産業分類：医薬品・医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、脈絡膜血管新生治療薬の世界市場を調査対象にし、脈絡膜血管新生治療薬の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（AVMOC-001、BB-3、BBT-007、DG-3、エントリモド、EWA-001、その他）、用途別分析（クリニック、病院、その他）、市場予測（2021年～2025年）、販売チャンネル・代理店分析情報などを整理しました。 ・市場概要 ・メーカー情報：Cellphire, Inc.、Humanetics Corporation、Cumberland Pharmaceuticals, Inc.、Chrysalis BioTherapeutics, Inc.、GNI Group Ltd.、Cleveland BioLabs, Inc.、Meabco A/S、Eli Lilly and Company、Diffusion Pharmaceuticals Inc.、INSYS Therapeutics, Inc.、ProCertus BioPharm Inc.、RxBio, Inc.、Neumedicines Inc.、RDD Pharma Ltd.、Pluristem Therapeutics Inc.、Onconova Therapeutics, Inc.、Soligenix, Inc.、RedHill Biopharma Ltd.、PharmaIN Corporation ・メーカー別販売量、売上、市場シェア ・脈絡膜血管新生治療薬の地域別市場分析 ・脈絡膜血管新生治療薬の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・脈絡膜血管新生治療薬のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・脈絡膜血管新生治療薬のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・脈絡膜血管新生治療薬の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・脈絡膜血管新生治療薬の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・脈絡膜血管新生治療薬の種類別市場規模2015-2020：AVMOC-001、BB-3、BBT-007、DG-3、エントリモド、EWA-001、その他 ・脈絡膜血管新生治療薬の用途別市場規模2015-2020：クリニック、病院、その他 ・脈絡膜血管新生治療薬の世界市場予測2021-2025：地域別、種類別、用途別 ・販売チャンネル・代理店分析 ・調査の結果・結論 |
Market Overview
The global Choroidal Neovascularization Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Choroidal Neovascularization Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Choroidal Neovascularization Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Choroidal Neovascularization Drug market has been segmented into
AVMOC-001
BB-3
BBT-007
DG-3
Entolimod
EWA-001
Others
By Application, Choroidal Neovascularization Drug has been segmented into:
Clinic
Hospital
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Choroidal Neovascularization Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Choroidal Neovascularization Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Choroidal Neovascularization Drug market.
The report offers in-depth assessment of the growth and other aspects of the Choroidal Neovascularization Drug market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Choroidal Neovascularization Drug Market Share Analysis
Choroidal Neovascularization Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Choroidal Neovascularization Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Choroidal Neovascularization Drug sales, revenue and market share for each player covered in this report.
The major players covered in Choroidal Neovascularization Drug are:
Cellphire, Inc.
Humanetics Corporation
Cumberland Pharmaceuticals, Inc.
Chrysalis BioTherapeutics, Inc.
GNI Group Ltd.
Cleveland BioLabs, Inc.
Meabco A/S
Eli Lilly and Company
Diffusion Pharmaceuticals Inc.
INSYS Therapeutics, Inc.
ProCertus BioPharm Inc.
RxBio, Inc.
Neumedicines Inc.
RDD Pharma Ltd.
Pluristem Therapeutics Inc.
Onconova Therapeutics, Inc.
Soligenix, Inc.
RedHill Biopharma Ltd.
PharmaIN Corporation
Among other players domestic and global, Choroidal Neovascularization Drug market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Choroidal Neovascularization Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Choroidal Neovascularization Drug, with price, sales, revenue and global market share of Choroidal Neovascularization Drug in 2018 and 2019.
Chapter 3, the Choroidal Neovascularization Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Choroidal Neovascularization Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Choroidal Neovascularization Drug market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Choroidal Neovascularization Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Choroidal Neovascularization Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Choroidal Neovascularization Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 AVMOC-001
1.2.3 BB-3
1.2.4 BBT-007
1.2.5 DG-3
1.2.6 Entolimod
1.2.7 EWA-001
1.2.8 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Choroidal Neovascularization Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Overview of Global Choroidal Neovascularization Drug Market
1.4.1 Global Choroidal Neovascularization Drug Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Cellphire, Inc.
2.1.1 Cellphire, Inc. Details
2.1.2 Cellphire, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Cellphire, Inc. SWOT Analysis
2.1.4 Cellphire, Inc. Product and Services
2.1.5 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Humanetics Corporation
2.2.1 Humanetics Corporation Details
2.2.2 Humanetics Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Humanetics Corporation SWOT Analysis
2.2.4 Humanetics Corporation Product and Services
2.2.5 Humanetics Corporation Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Cumberland Pharmaceuticals, Inc.
2.3.1 Cumberland Pharmaceuticals, Inc. Details
2.3.2 Cumberland Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Cumberland Pharmaceuticals, Inc. SWOT Analysis
2.3.4 Cumberland Pharmaceuticals, Inc. Product and Services
2.3.5 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Chrysalis BioTherapeutics, Inc.
2.4.1 Chrysalis BioTherapeutics, Inc. Details
2.4.2 Chrysalis BioTherapeutics, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Chrysalis BioTherapeutics, Inc. SWOT Analysis
2.4.4 Chrysalis BioTherapeutics, Inc. Product and Services
2.4.5 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 GNI Group Ltd.
2.5.1 GNI Group Ltd. Details
2.5.2 GNI Group Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 GNI Group Ltd. SWOT Analysis
2.5.4 GNI Group Ltd. Product and Services
2.5.5 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Cleveland BioLabs, Inc.
2.6.1 Cleveland BioLabs, Inc. Details
2.6.2 Cleveland BioLabs, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Cleveland BioLabs, Inc. SWOT Analysis
2.6.4 Cleveland BioLabs, Inc. Product and Services
2.6.5 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Meabco A/S
2.7.1 Meabco A/S Details
2.7.2 Meabco A/S Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Meabco A/S SWOT Analysis
2.7.4 Meabco A/S Product and Services
2.7.5 Meabco A/S Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Eli Lilly and Company
2.8.1 Eli Lilly and Company Details
2.8.2 Eli Lilly and Company Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Eli Lilly and Company SWOT Analysis
2.8.4 Eli Lilly and Company Product and Services
2.8.5 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Diffusion Pharmaceuticals Inc.
2.9.1 Diffusion Pharmaceuticals Inc. Details
2.9.2 Diffusion Pharmaceuticals Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Diffusion Pharmaceuticals Inc. SWOT Analysis
2.9.4 Diffusion Pharmaceuticals Inc. Product and Services
2.9.5 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 INSYS Therapeutics, Inc.
2.10.1 INSYS Therapeutics, Inc. Details
2.10.2 INSYS Therapeutics, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 INSYS Therapeutics, Inc. SWOT Analysis
2.10.4 INSYS Therapeutics, Inc. Product and Services
2.10.5 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 ProCertus BioPharm Inc.
2.11.1 ProCertus BioPharm Inc. Details
2.11.2 ProCertus BioPharm Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 ProCertus BioPharm Inc. SWOT Analysis
2.11.4 ProCertus BioPharm Inc. Product and Services
2.11.5 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 RxBio, Inc.
2.12.1 RxBio, Inc. Details
2.12.2 RxBio, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 RxBio, Inc. SWOT Analysis
2.12.4 RxBio, Inc. Product and Services
2.12.5 RxBio, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 Neumedicines Inc.
2.13.1 Neumedicines Inc. Details
2.13.2 Neumedicines Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Neumedicines Inc. SWOT Analysis
2.13.4 Neumedicines Inc. Product and Services
2.13.5 Neumedicines Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.14 RDD Pharma Ltd.
2.14.1 RDD Pharma Ltd. Details
2.14.2 RDD Pharma Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 RDD Pharma Ltd. SWOT Analysis
2.14.4 RDD Pharma Ltd. Product and Services
2.14.5 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.15 Pluristem Therapeutics Inc.
2.15.1 Pluristem Therapeutics Inc. Details
2.15.2 Pluristem Therapeutics Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Pluristem Therapeutics Inc. SWOT Analysis
2.15.4 Pluristem Therapeutics Inc. Product and Services
2.15.5 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.16 Onconova Therapeutics, Inc.
2.16.1 Onconova Therapeutics, Inc. Details
2.16.2 Onconova Therapeutics, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Onconova Therapeutics, Inc. SWOT Analysis
2.16.4 Onconova Therapeutics, Inc. Product and Services
2.16.5 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.17 Soligenix, Inc.
2.17.1 Soligenix, Inc. Details
2.17.2 Soligenix, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Soligenix, Inc. SWOT Analysis
2.17.4 Soligenix, Inc. Product and Services
2.17.5 Soligenix, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.18 RedHill Biopharma Ltd.
2.18.1 RedHill Biopharma Ltd. Details
2.18.2 RedHill Biopharma Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 RedHill Biopharma Ltd. SWOT Analysis
2.18.4 RedHill Biopharma Ltd. Product and Services
2.18.5 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.19 PharmaIN Corporation
2.19.1 PharmaIN Corporation Details
2.19.2 PharmaIN Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 PharmaIN Corporation SWOT Analysis
2.19.4 PharmaIN Corporation Product and Services
2.19.5 PharmaIN Corporation Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Choroidal Neovascularization Drug Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Choroidal Neovascularization Drug Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Choroidal Neovascularization Drug Manufacturer Market Share in 2019
3.3.2 Top 6 Choroidal Neovascularization Drug Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Choroidal Neovascularization Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Choroidal Neovascularization Drug Sales and Market Share by Regions (2015-2020)
4.1.2 Global Choroidal Neovascularization Drug Revenue and Market Share by Regions (2015-2020)
4.2 North America Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
4.3 Europe Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
4.5 South America Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Choroidal Neovascularization Drug Sales, Revenue and Market Share by Country
5.1.1 North America Choroidal Neovascularization Drug Sales and Market Share by Country (2015-2020)
5.1.2 North America Choroidal Neovascularization Drug Revenue and Market Share by Country (2015-2020)
5.2 United States Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
5.3 Canada Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
5.4 Mexico Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Choroidal Neovascularization Drug Sales, Revenue and Market Share by Country
6.1.1 Europe Choroidal Neovascularization Drug Sales and Market Share by Country (2015-2020)
6.1.2 Europe Choroidal Neovascularization Drug Revenue and Market Share by Country (2015-2020)
6.2 Germany Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
6.3 UK Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
6.4 France Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
6.5 Russia Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
6.6 Italy Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Choroidal Neovascularization Drug Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Choroidal Neovascularization Drug Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Choroidal Neovascularization Drug Revenue and Market Share by Regions (2015-2020)
7.2 China Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
7.3 Japan Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
7.4 Korea Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
7.5 India Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
7.7 Australia Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Choroidal Neovascularization Drug Sales, Revenue and Market Share by Country
8.1.1 South America Choroidal Neovascularization Drug Sales and Market Share by Country (2015-2020)
8.1.2 South America Choroidal Neovascularization Drug Revenue and Market Share by Country (2015-2020)
8.2 Brazil Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
8.3 Argentina Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Choroidal Neovascularization Drug Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Choroidal Neovascularization Drug Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Choroidal Neovascularization Drug Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
9.3 Turkey Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
9.4 Egypt Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
9.5 South Africa Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Choroidal Neovascularization Drug Sales and Market Share by Type (2015-2020)
10.2 Global Choroidal Neovascularization Drug Revenue and Market Share by Type (2015-2020)
10.3 Global Choroidal Neovascularization Drug Price by Type (2015-2020)
11 Global Choroidal Neovascularization Drug Market Segment by Application
11.1 Global Choroidal Neovascularization Drug Sales Market Share by Application (2015-2020)
11.2 Global Choroidal Neovascularization Drug Revenue Market Share by Application (2015-2020)
11.3 Global Choroidal Neovascularization Drug Price by Application (2015-2020)
12 Market Forecast
12.1 Global Choroidal Neovascularization Drug Sales, Revenue and Growth Rate (2021-2025)
12.2 Choroidal Neovascularization Drug Market Forecast by Regions (2021-2025)
12.2.1 North America Choroidal Neovascularization Drug Market Forecast (2021-2025)
12.2.2 Europe Choroidal Neovascularization Drug Market Forecast (2021-2025)
12.2.3 Asia-Pacific Choroidal Neovascularization Drug Market Forecast (2021-2025)
12.2.4 South America Choroidal Neovascularization Drug Market Forecast (2021-2025)
12.2.5 Middle East & Africa Choroidal Neovascularization Drug Market Forecast (2021-2025)
12.3 Choroidal Neovascularization Drug Market Forecast by Type (2021-2025)
12.3.1 Global Choroidal Neovascularization Drug Sales Forecast by Type (2021-2025)
12.3.2 Global Choroidal Neovascularization Drug Market Share Forecast by Type (2021-2025)
12.4 Choroidal Neovascularization Drug Market Forecast by Application (2021-2025)
12.4.1 Global Choroidal Neovascularization Drug Sales Forecast by Application (2021-2025)
12.4.2 Global Choroidal Neovascularization Drug Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Choroidal Neovascularization Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Choroidal Neovascularization Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Choroidal Neovascularization Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Cellphire, Inc. Basic Information, Manufacturing Base and Competitors
Table 8. Cellphire, Inc. Choroidal Neovascularization Drug Major Business
Table 9. Cellphire, Inc. Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 10. Cellphire, Inc. SWOT Analysis
Table 11. Cellphire, Inc. Choroidal Neovascularization Drug Product and Services
Table 12. Cellphire, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Humanetics Corporation Basic Information, Manufacturing Base and Competitors
Table 14. Humanetics Corporation Choroidal Neovascularization Drug Major Business
Table 15. Humanetics Corporation Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 16. Humanetics Corporation SWOT Analysis
Table 17. Humanetics Corporation Choroidal Neovascularization Drug Product and Services
Table 18. Humanetics Corporation Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Cumberland Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 20. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Major Business
Table 21. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 22. Cumberland Pharmaceuticals, Inc. SWOT Analysis
Table 23. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product and Services
Table 24. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Chrysalis BioTherapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 26. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Major Business
Table 27. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 28. Chrysalis BioTherapeutics, Inc. SWOT Analysis
Table 29. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product and Services
Table 30. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. GNI Group Ltd. Basic Information, Manufacturing Base and Competitors
Table 32. GNI Group Ltd. Choroidal Neovascularization Drug Major Business
Table 33. GNI Group Ltd. Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 34. GNI Group Ltd. SWOT Analysis
Table 35. GNI Group Ltd. Choroidal Neovascularization Drug Product and Services
Table 36. GNI Group Ltd. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Cleveland BioLabs, Inc. Basic Information, Manufacturing Base and Competitors
Table 38. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Major Business
Table 39. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 40. Cleveland BioLabs, Inc. SWOT Analysis
Table 41. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product and Services
Table 42. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Meabco A/S Basic Information, Manufacturing Base and Competitors
Table 44. Meabco A/S Choroidal Neovascularization Drug Major Business
Table 45. Meabco A/S Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 46. Meabco A/S SWOT Analysis
Table 47. Meabco A/S Choroidal Neovascularization Drug Product and Services
Table 48. Meabco A/S Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 50. Eli Lilly and Company Choroidal Neovascularization Drug Major Business
Table 51. Eli Lilly and Company Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 52. Eli Lilly and Company SWOT Analysis
Table 53. Eli Lilly and Company Choroidal Neovascularization Drug Product and Services
Table 54. Eli Lilly and Company Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Diffusion Pharmaceuticals Inc. Basic Information, Manufacturing Base and Competitors
Table 56. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Major Business
Table 57. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 58. Diffusion Pharmaceuticals Inc. SWOT Analysis
Table 59. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product and Services
Table 60. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. INSYS Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 62. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Major Business
Table 63. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 64. INSYS Therapeutics, Inc. SWOT Analysis
Table 65. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product and Services
Table 66. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. ProCertus BioPharm Inc. Basic Information, Manufacturing Base and Competitors
Table 68. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Major Business
Table 69. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 70. ProCertus BioPharm Inc. SWOT Analysis
Table 71. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product and Services
Table 72. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 73. RxBio, Inc. Basic Information, Manufacturing Base and Competitors
Table 74. RxBio, Inc. Choroidal Neovascularization Drug Major Business
Table 75. RxBio, Inc. Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 76. RxBio, Inc. SWOT Analysis
Table 77. RxBio, Inc. Choroidal Neovascularization Drug Product and Services
Table 78. RxBio, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 79. Neumedicines Inc. Basic Information, Manufacturing Base and Competitors
Table 80. Neumedicines Inc. Choroidal Neovascularization Drug Major Business
Table 81. Neumedicines Inc. Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 82. Neumedicines Inc. SWOT Analysis
Table 83. Neumedicines Inc. Choroidal Neovascularization Drug Product and Services
Table 84. Neumedicines Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 85. RDD Pharma Ltd. Basic Information, Manufacturing Base and Competitors
Table 86. RDD Pharma Ltd. Choroidal Neovascularization Drug Major Business
Table 87. RDD Pharma Ltd. Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 88. RDD Pharma Ltd. SWOT Analysis
Table 89. RDD Pharma Ltd. Choroidal Neovascularization Drug Product and Services
Table 90. RDD Pharma Ltd. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 91. Pluristem Therapeutics Inc. Basic Information, Manufacturing Base and Competitors
Table 92. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Major Business
Table 93. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 94. Pluristem Therapeutics Inc. SWOT Analysis
Table 95. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product and Services
Table 96. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 97. Onconova Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 98. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Major Business
Table 99. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 100. Onconova Therapeutics, Inc. SWOT Analysis
Table 101. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product and Services
Table 102. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 103. Soligenix, Inc. Basic Information, Manufacturing Base and Competitors
Table 104. Soligenix, Inc. Choroidal Neovascularization Drug Major Business
Table 105. Soligenix, Inc. Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 106. Soligenix, Inc. SWOT Analysis
Table 107. Soligenix, Inc. Choroidal Neovascularization Drug Product and Services
Table 108. Soligenix, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 109. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Type and Application
Table 110. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Major Business
Table 111. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 112. RedHill Biopharma Ltd. SWOT Analysis
Table 113. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product and Services
Table 114. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 115. PharmaIN Corporation Basic Information, Manufacturing Base and Competitors
Table 116. PharmaIN Corporation Choroidal Neovascularization Drug Major Business
Table 117. PharmaIN Corporation Choroidal Neovascularization Drug Total Revenue (USD Million) (2018-2019)
Table 118. PharmaIN Corporation SWOT Analysis
Table 119. PharmaIN Corporation Choroidal Neovascularization Drug Product and Services
Table 120. PharmaIN Corporation Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 121. Global Choroidal Neovascularization Drug Sales by Manufacturer (2018-2019) (K Pcs)
Table 122. Global Choroidal Neovascularization Drug Revenue by Manufacturer (2018-2019) (USD Million)
Table 123. Global Choroidal Neovascularization Drug Sales by Regions (2015-2020) (K Pcs)
Table 124. Global Choroidal Neovascularization Drug Sales Market Share by Regions (2015-2020)
Table 125. Global Choroidal Neovascularization Drug Revenue by Regions (2015-2020) (USD Million)
Table 126. North America Choroidal Neovascularization Drug Sales by Countries (2015-2020) (K Pcs)
Table 127. North America Choroidal Neovascularization Drug Sales Market Share by Countries (2015-2020)
Table 128. North America Choroidal Neovascularization Drug Revenue by Countries (2015-2020) (USD Million)
Table 129. North America Choroidal Neovascularization Drug Revenue Market Share by Countries (2015-2020)
Table 130. Europe Choroidal Neovascularization Drug Sales by Countries (2015-2020) (K Pcs)
Table 131. Europe Choroidal Neovascularization Drug Sales Market Share by Countries (2015-2020)
Table 132. Europe Choroidal Neovascularization Drug Revenue by Countries (2015-2020) (USD Million)
Table 133. Asia-Pacific Choroidal Neovascularization Drug Sales by Regions (2015-2020) (K Pcs)
Table 134. Asia-Pacific Choroidal Neovascularization Drug Sales Market Share by Regions (2015-2020)
Table 135. Asia-Pacific Choroidal Neovascularization Drug Revenue by Regions (2015-2020) (USD Million)
Table 136. South America Choroidal Neovascularization Drug Sales by Countries (2015-2020) (K Pcs)
Table 137. South America Choroidal Neovascularization Drug Sales Market Share by Countries (2015-2020)
Table 138. South America Choroidal Neovascularization Drug Revenue by Countries (2015-2020) (USD Million)
Table 139. South America Choroidal Neovascularization Drug Revenue Market Share by Countries (2015-2020)
Table 140. Middle East & Africa Choroidal Neovascularization Drug Sales by Countries (2015-2020) (K Pcs)
Table 141. Middle East & Africa Choroidal Neovascularization Drug Sales Market Share by Countries (2015-2020)
Table 142. Middle East & Africa Choroidal Neovascularization Drug Revenue by Countries (2015-2020) (USD Million)
Table 143. Middle East & Africa Choroidal Neovascularization Drug Revenue Market Share by Countries (2015-2020)
Table 144. Global Choroidal Neovascularization Drug Sales by Type (2015-2020) (K Pcs)
Table 145. Global Choroidal Neovascularization Drug Sales Share by Type (2015-2020)
Table 146. Global Choroidal Neovascularization Drug Revenue by Type (2015-2020) (USD Million)
Table 147. Global Choroidal Neovascularization Drug Revenue Share by Type (2015-2020)
Table 148. Global Choroidal Neovascularization Drug Sales by Application (2015-2020) (K Pcs)
Table 149. Global Choroidal Neovascularization Drug Sales Share by Application (2015-2020)
Table 150. Global Choroidal Neovascularization Drug Sales Forecast by Regions (2021-2025) (K Pcs)
Table 151. Global Choroidal Neovascularization Drug Market Share Forecast by Regions (2021-2025)
Table 152. Global Choroidal Neovascularization Drug Sales Forecast by Type (2021-2025) (K Pcs)
Table 153. Global Choroidal Neovascularization Drug Market Share Forecast by Type (2021-2025)
Table 154. Global Choroidal Neovascularization Drug Sales Forecast by Application (2021-2025)
Table 155. Global Choroidal Neovascularization Drug Market Share Forecast by Application (2021-2025)
Table 156. Direct Channel Pros & Cons
Table 157. Indirect Channel Pros & Cons
Table 158. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Choroidal Neovascularization Drug Picture
Figure 2. Global Sales Market Share of Choroidal Neovascularization Drug by Type in 2019
Figure 3. AVMOC-001 Picture
Figure 4. BB-3 Picture
Figure 5. BBT-007 Picture
Figure 6. DG-3 Picture
Figure 7. Entolimod Picture
Figure 8. EWA-001 Picture
Figure 9. Others Picture
Figure 10. Choroidal Neovascularization Drug Sales Market Share by Application in 2018
Figure 11. Clinic Picture
Figure 12. Hospital Picture
Figure 13. Others Picture
Figure 14. Global Choroidal Neovascularization Drug Market Status and Outlook (2015-2025) (USD Million)
Figure 15. United States Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Canada Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Mexico Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Germany Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 19. France Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 20. UK Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Russia Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Italy Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 23. China Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Japan Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Korea Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 26. India Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Southeast Asia Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Australia Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 29. Brazil Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Egypt Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Saudi Arabia Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 32. South Africa Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 33. Turkey Choroidal Neovascularization Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 34. Global Choroidal Neovascularization Drug Sales Market Share by Manufacturer in 2019
Figure 35. Global Choroidal Neovascularization Drug Revenue Market Share by Manufacturer in 2019
Figure 36. Top 3 Choroidal Neovascularization Drug Manufacturer (Revenue) Market Share in 2019
Figure 37. Top 6 Choroidal Neovascularization Drug Manufacturer (Revenue) Market Share in 2019
Figure 38. Key Manufacturer Market Share Trend
Figure 39. Global Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 40. Global Choroidal Neovascularization Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 41. Global Choroidal Neovascularization Drug Revenue Market Share by Regions (2015-2020)
Figure 42. Global Choroidal Neovascularization Drug Revenue Market Share by Regions in 2018
Figure 43. North America Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
Figure 44. Europe Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
Figure 45. Asia-Pacific Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
Figure 46. South America Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
Figure 47. Middle East & Africa Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020)
Figure 48. North America Choroidal Neovascularization Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 49. North America Choroidal Neovascularization Drug Sales Market Share by Countries (2015-2020)
Figure 50. North America Choroidal Neovascularization Drug Sales Market Share by Countries in 2018
Figure 51. North America Choroidal Neovascularization Drug Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 52. North America Choroidal Neovascularization Drug Revenue Market Share by Countries in 2018
Figure 53. United States Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 54. Canada Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 55. Mexico Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 56. Europe Choroidal Neovascularization Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 57. Europe Choroidal Neovascularization Drug Revenue Market Share by Countries (2015-2020)
Figure 58. Europe Choroidal Neovascularization Drug Revenue Market Share by Countries in 2019
Figure 59. Germany Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 60. UK Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 61. France Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 62. Russia Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 63. Italy Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 64. Asia-Pacific Choroidal Neovascularization Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 65. Asia-Pacific Choroidal Neovascularization Drug Sales Market Share by Regions 2019
Figure 66. Asia-Pacific Choroidal Neovascularization Drug Revenue Market Share by Regions 2019
Figure 67. China Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 68. Japan Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 69. Korea Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 70. India Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 71. Southeast Asia Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 72. South America Choroidal Neovascularization Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 73. South America Choroidal Neovascularization Drug Sales Market Share by Countries in 2019
Figure 74. South America Choroidal Neovascularization Drug Revenue Market Share by Countries in 2019
Figure 75. Brazil Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 76. Argentina Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 77. Middle East and Africa Choroidal Neovascularization Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 78. Middle East and Africa Choroidal Neovascularization Drug Sales Market Share by Countries in 2019
Figure 79. Middle East and Africa Choroidal Neovascularization Drug Revenue Market Share by Countries (2015-2020)
Figure 80. Middle East and Africa Choroidal Neovascularization Drug Revenue Market Share by Countries in 2019
Figure 81. Saudi Arabia Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 82. Egypt Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 83. Turkey Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 84. South Africa Choroidal Neovascularization Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 85. Global Choroidal Neovascularization Drug Sales and Growth Rate (2021-2025) (K Pcs)
Figure 86. Global Choroidal Neovascularization Drug Revenue and Growth Rate (2021-2025) (USD Million)
Figure 87. North America Sales Choroidal Neovascularization Drug Market Forecast (2021-2025) (K Pcs)
Figure 88. Europe Sales Choroidal Neovascularization Drug Market Forecast (2021-2025) (K Pcs)
Figure 89. Asia-Pacific Sales Choroidal Neovascularization Drug Market Forecast (2021-2025) (K Pcs)
Figure 90. South America Sales Choroidal Neovascularization Drug Market Forecast (2021-2025) (K Pcs)
Figure 91. Middle East & Africa Sales Choroidal Neovascularization Drug Market Forecast (2021-2025) (K Pcs)
Figure 92. Sales Channel: Direct Channel vs Indirect Channel
甲状腺機能低下症治療の世界市場 2020年 Market Overview The global Hypothyroidism Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Hypothyroidism Drug marke…- 小売用医薬品の世界市場 2020年 Market Overview The global Retail Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 2.8% in the forecast period of 2020 to 2025 and will expected to reach USD 1350.1 million by 2025, from USD 1211 million in 2019. The Retail Drug market report …
- アンカ血管炎薬の世界市場 2020年 Market Overview The global Anca Vasculitis Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Anca Vasculitis Drug mar…
- スニチニブ薬の世界市場 2020年 Market Overview The global Sunitinib Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Sunitinib Drug market report p…
- コクシジオイデス症薬剤の世界市場 2020年 Market Overview The global Coccidioidomycosis Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Coccidioidomycosis Dr…